Rosetta Genomics to Host Business Update and 2014 Year End Financials Conference Call on March 17, 2015
March 10 2015 - 11:31AM
Business Wire
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and
provider of microRNA-based molecular diagnostics, today announced
that following the close of the U.S. stock market on Monday, March
16, 2015, the Company will file its financial results for the year
ended December 31, 2014 on Form 20-F with the U.S. Securities and
Exchange Commission (“SEC”). The Form 20-F includes audited
consolidated financial statements, as well as additional
information regarding the Company. Once filed, the Form 20-F will
be available at www.sec.gov and at www.rosettagenomics.com.
Kenneth A. Berlin, President and Chief Executive Officer of
Rosetta Genomics, and Ron Kalfus, Chief Financial Officer of
Rosetta Genomics, will host a conference call on Tuesday, March 17,
2015 at 10:00 a.m. Eastern time to provide an update on the
Company’s business and respond to questions.
Individuals interested in listening to the conference call may
do so by dialing (866) 239-5859, or for international callers (702)
495-1913. The conference ID number is 4557508. The call is also
being webcast, and can be accessed on the investor relations
section of the Company’s Web site at www.rosettagenomics.com.
A telephone replay will be available through March 24, 2015 by
dialing (855) 859-2056 or for international callers (404) 537-3406,
and entering the Conference ID number 4557508. The webcast will be
available on the Company’s website for 30 days following the
completion of the call.
About Rosetta Genomics
Rosetta develops and commercializes a full range of
microRNA-based molecular diagnostics. Founded in 2000, Rosetta’s
integrative research platform combining bioinformatics and
state-of-the-art laboratory processes has led to the discovery of
hundreds of biologically validated novel human microRNAs. Building
on its strong patent position and proprietary platform
technologies, Rosetta is working on the application of these
technologies in the development and commercialization of a full
range of microRNA-based diagnostic tools. Rosetta’s cancer testing
services are commercially available through its Philadelphia-based
CAP-accredited, CLIA-certified lab.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future
expectations, plans and prospects, including without limitation,
Rosetta’s development or commercialization of molecular diagnostics
or therapeutics, the market acceptance of Rosetta’s cancer testing
services, particularly the Rosetta Cancer Origin Test™ and the
thyroid assay, Rosetta’s development of personalized medicine
products and services, constitute forward-looking statements for
the purposes of the safe harbor provisions under The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors, including those risks
more fully discussed in the "Risk Factors" section of Rosetta’s
Annual Report on Form 20-F for the year ended December 31,
2013 as filed with the SEC. In addition, any forward-looking
statements represent Rosetta’s views only as of the date of this
release and should not be relied upon as representing its views as
of any subsequent date. Rosetta does not assume any obligation to
update any forward-looking statements unless required by law.
# # #
Company Contact:Rosetta GenomicsKen Berlin,
609-419-9003President &
CEOinvestors@rosettagenomics.comorInvestor Contacts:LHAAnne
Marie Fields, 212-838-3777afields@lhai.comorBruce Voss,
310-691-7100bvoss@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Apr 2024 to May 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From May 2023 to May 2024